Interferon- mRNA attenuates its own translation by activating PKR: A molecular basis for the therapeutic effect of interferon- in multiple sclerosis

被引:0
|
作者
Raymond Kaempfer
机构
[1] The Hebrew University-Hadassah Medical School,Department of Molecular Virology
来源
Cell Research | 2006年 / 16卷
关键词
interferon -γ mRNA; RNA pseudoknot; translational control; PKR; eIF2; multiple sclerosis; interferon -β;
D O I
暂无
中图分类号
学科分类号
摘要
PKR, the interferon (IFN)-inducible protein kinase activated by double-stranded RNA, inhibits translation by phosphorylating the initiation factor eIF2α chain. Uniquely, human IFN-γ mRNA uses local activation of PKR in the cell to control its own translation yield. IFN-γ mRNA activates PKR through a structure in its 5′- region harboring a pseudoknot which is critical for PKR activation. Mutations that impair pseudoknot stability reduce the ability of IFN-γ mRNA to activate PKR and strongly increase its translation efficiency. The cis-acting RNA element in IFN-γ mRNA functions as a biological sensor of intracellular PKR levels. During an immune response, as IFN-γ and other inflammatory cytokines build up in the cell's microenvironment, they act to induce higher levels of PKR in the cell, resulting in a more extensive activation of PKR by IFN-γ mRNA. With the resulting phosphorylation of eIF2α, a negative feedback loop is created and the production of IFN-γ is progressively attenuated. We propose that the therapeutic effect of IFN-β in multiple sclerosis may rest, at least in part, on its exquisite ability to induce high levels of PKR in the cell and thereby to limit IFN-γ mRNA translation through this negative feedback loop, blocking the excessive IFN-γ gene expression that precedes clinical attacks.
引用
收藏
页码:148 / 153
页数:5
相关论文
共 50 条
  • [21] Psychiatric side effects of interferon-β in multiple sclerosis
    Goeb, JL
    Even, C
    Nicolas, G
    Gohier, B
    Dubas, F
    Garré, JB
    [J]. EUROPEAN PSYCHIATRY, 2006, 21 (03) : 186 - 193
  • [22] Interferon-β therapy for multiple sclerosis is linked with headache
    [J]. Nature Clinical Practice Neurology, 2006, 2 (10): : 520 - 521
  • [23] Immmunomodulation by quercetin and interferon-β in multiple sclerosis patients
    Chadha, Kailash
    Sternberg, Zohara
    Lieberman, Alicia
    Drake, Allison
    Weinstock-Guttman, Bianca
    Munschauer, Frederick
    [J]. CYTOKINE, 2009, 48 (1-2) : 108 - 108
  • [24] Migraines linked to interferon-β treatment of multiple sclerosis
    Khromov, A
    Segal, M
    Nissinoff, J
    Fast, A
    [J]. AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2005, 84 (08) : 644 - 647
  • [25] Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies
    Santos, Roseane
    Weinstock-Guttman, Bianca
    Tamano-Blanco, Miriam
    Badgett, Darlene
    Zivadinov, Robert
    Justinger, Theresa
    Munschauer, Frederick, III
    Ramanathan, Murali
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2006, 176 (1-2) : 125 - 133
  • [26] Interferon-β-1aA Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis
    Stephen M. Holliday
    Paul Benfield
    [J]. BioDrugs, 1997, 8 : 317 - 330
  • [27] Cell type-specific responses to interferon-β: implications for understanding the mechanism of interferon-β therapy in multiple sclerosis
    van Boxel-Dezaire, Anette H. H.
    Fisher, Elizabeth
    Ransohoff, Richard M.
    Rudick, Richard A.
    Stark, George R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (08) : 997 - 998
  • [28] Interferon-β-1b A Review of its Use in Multiple Sclerosis
    Plosker, Greg L.
    [J]. CNS DRUGS, 2011, 25 (01) : 67 - 88
  • [29] Dose and frequency of administration of interferon-β affect its efficacy in multiple sclerosis
    Sharief, MK
    [J]. CLINICAL DRUG INVESTIGATION, 2003, 23 (09) : 551 - 559
  • [30] Interferon-β-1bA Review of its Use in Multiple Sclerosis
    Greg L. Plosker
    [J]. CNS Drugs, 2011, 25 : 67 - 88